Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial of UDP-003 for the treatment of atherosclerosis

X
Trial Profile

Clinical trial of UDP-003 for the treatment of atherosclerosis

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UDP-003 (Primary)
  • Indications Atherosclerosis
  • Focus Adverse reactions
  • Sponsors Cyclarity Therapeutics
  • Most Recent Events

    • 28 Sep 2021 New trial record
    • 23 Sep 2021 According to an underdog pharmaceuticals, the company expect to begin clinical trials in 2023.
    • 04 Jul 2021 According to an Underdog Pharmaceuticals media release, company concluded a successful meeting with the Medicines and Health products Regulatory Agency (MHRA) of the UK.The MHRA supported inclusion of trial participants with asymptomatic, stable, non-culprit plaques, as long as subjects have no diagnosed CVD condition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top